Evofem extends Adjuvant convertible note maturity to April 2026; prepayment restricted

Evofem Biosciences, Inc.

Notes become due on earliest of: 6 months after Oct 13, 2025 (April 13, 2026), change of control, or acceleration.
No prepayment permitted before April 13, 2026 without Adjuvant's written consent.
Amendment dated October 13, 2025 modifies the October 2020 Securities Purchase Agreement.
Adjuvant Global Health Technology Fund holds the convertible promissory notes covered by the amendment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.